Over the past 12 years, medical treatment for renal cell carcinoma (RCC) has transitioned
from a nonspecific immune approach (in the cytokine era), to targeted therapy against …

The diagnosis and management of renal cell carcinoma have changed remarkably rapidly.
Although the incidence of renal cell carcinoma has been increasing, survival has improved …

Purpose This phase III trial evaluated the efficacy and safety of pazopanib versus placebo in
patients with locally advanced renal cell carcinoma (RCC) at high risk for relapse after …

Considerable progress has been made in the treatment of patients with renal cell carcinoma,
with innovative surgical and systemic strategies revolutionising the management of this …

Abstract Type I interferons (IFN-I) are well-known inducers of tumor cell apoptosis and
antiangiogenesis via signaling through a common receptor interferon alpha receptor …

Standard-of-care management of renal cell carcinoma (RCC) indisputably relies on surgery
for low-risk localized tumours and systemic treatment for poor-prognosis metastatic disease …

The most common renal cancer is renal cell carcinoma (RCC), which arises from the renal
parenchyma. The global incidence of RCC has increased over the past two decades by 2 …

Aim Interferon-α (IFN-α) has been extensively explored for its efficacy in various disease
conditions and is currently used as a standard treatment in several of these. Its use is …

Background Organ-confined renal-cell carcinoma is associated with tumour progression in
up to 50% of patients after radical nephrectomy. At present, no effective adjuvant treatment is …

Background Treatment of localised renal cell carcinoma consists of partial or radical
nephrectomy. A substantial proportion of patients are at risk for recurrence because no …